ALK and non-small cell lung carcinoma: Molecularly targeted therapies have produced substantial clinical benefits in about 20% of non-small cell lung cancer (NSCLC) patients, including a 4% subgroup harboring the anaplastic lymphoma kinase (ALK) gene rearrangements1.